Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 735-pelvic-evisceration-radical-hysterectomy-and-radical-vulvectomy-without-cc-mcc
    Ask Trek AI about this page

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    DRG 735 covers pelvic evisceration, radical hysterectomy, and radical vulvectomy cases without Major Complication or Comorbidity or Complication or Comorbidity and defines the clinical scope of high-complexity pelvic oncologic surgery. This Diagnosis-Related Group matters for inpatient reimbursement because procedure selection and documentation of comorbid conditions determine grouping and associated Medicare payment.

    Customize your policy alerts

    Sign up for drg 735 policy alerts

    Get alerted when payer policies referencing 735 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 735 Overview

    DRG 735 encompasses extensive pelvic oncologic resections including pelvic evisceration, radical hysterectomy, and radical vulvectomy performed without a Major Complication or Comorbidity and without a Complication or Comorbidity. These procedures are high-complexity, often multidisciplinary surgeries for advanced gynecologic malignancy or refractory pelvic disease. For Medicare payment, this Diagnosis-Related Group groups cases of comparable resource use and sets inpatient reimbursement parameters tied to the principal procedure and absence of higher-severity diagnoses. Accurate coding of procedures and comorbidity status determines assignment to this Diagnosis-Related Group and affects the hospital’s inpatient prospective payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating perioperative blood loss minimization and transfusion strategies for patients undergoing pelvic evisceration or radical hysterectomy: these studies test protocols such as enhanced intraoperative hemostatic techniques, restrictive transfusion thresholds, and use of cell salvage in a high-bleed, high-complexity surgical population primarily composed of patients with advanced gynecologic malignancies. The objective is to reduce intraoperative transfusions, complications, and length of stay; results inform surgeons and hospital administrators about best practices to lower complication-related costs and resource use.
    • Comparative effectiveness studies of different surgical approaches and perioperative care pathways in radical vulvectomy and radical hysterectomy: randomized or prospective cohort studies compare open versus minimally invasive techniques where applicable, extent of lymphadenectomy, or standardized enhanced recovery after surgery (ERAS) pathways in patients without major comorbidities (no CC/MCC). These trials address which approaches yield lower complication rates, faster functional recovery, and shorter hospitalization, providing evidence that influences DRG-level resource utilization, coding, and payer coverage decisions.
    • Post-discharge and survivorship outcomes research focusing on functional recovery, wound complications, and quality of life after pelvic exenteration-type procedures: longitudinal observational studies and registry-based research follow patients after discharge to quantify rates of readmission, wound breakdown, urinary or bowel diversion complications, and long-term quality-of-life metrics in this surgically intense cohort. Such data are critical for care managers and payers to plan post-acute care needs, bundle payments or case management resources, and to identify opportunities to reduce costly readmissions and improve value of care.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    744-D-C-CONIZATION-LAPAROSCOPY-AND-TUBAL-INTERRUPTION-WITH-CC-MCC

    D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.